Welsh government funds GSK's Bexsero; Weber says Takeda turnaround involves vaccines focus;

> The Welsh government has agreed to fund GlaxoSmithKline's ($GSK) meningitis B vaccine Bexsero for every baby in the country at a cost of £7.7 million. Report

> Shortly after becoming Takeda CEO, Christophe Weber said the turnaround there has quickened, with a renewed focus on generics, emerging markets and vaccines. Report

> Two novel Ebola vaccines protected macaques against the strain of the virus responsible for the deadly outbreak with no side effects. Story (reg. req.)

> Samsung Pharmaceutical agreed to manufacture and sell GemVax & KAEL Co.'s pancreatic cancer vaccine Rivavax in South Korea until 2020 for 5 billion won ($4.5 million). Report

> Merck ($MRK) and Advaxis ($ADXS) announced enrollment in a Phase I/II study of prostate cancer vaccine ADXS-PSA. in combination with Merck's Keytruda. Release

Suggested Articles

As COVID-19 vaccines advance, the FDA held an expert hearing Thursday to talk safety, efficacy, distribution plans and vaccine confidence—plus more. 

Moderna, racing ahead with COVID-19 vaccine R&D, completed enrollment for its late-stage trial—and moved one step closer to approval.

Since the FDA released new COVID-19 vaccine guidance, HHS Secretary Alex Azar has discussed firing FDA Commissioner Stephen Hahn, Politico reports.